|
61 |
Bispecific antibodies retarget murine T cell cytotoxicity against syngeneic breast cancer in vitro and in vivo
Enthalten in Cancer immunology immunotherapy Bd. 40, Nr. 3, date:5.1995: 182-190
|
|
|
|
62 |
Intraperitoneal therapy of ovarian cancer with retargeted lymphocytes by bispecific monoclonal antibodies and interleukin-2
Enthalten in European surgery Bd. 27, Nr. 2, date:3.1995: 90-92
|
|
|
|
63 |
Real-time kinetic analysis applied to the production of bispecific monoclonal antibodies for radioimmunodetection of cancer
Enthalten in International journal of clinical & laboratory research Bd. 23, Nr. 1-4, date:12.1993: 199-205
|
|
|
|
64 |
Comparative efficiencies of bispecific F(ab′γ)2 and chimeric mouse/human IgG antibodies in recruiting cellular effectors for cytotoxicity via Fcγ receptors
Enthalten in Cancer immunology immunotherapy Bd. 34, Nr. 6, date:11.1992: 361-369
|
|
|
|
65 |
Bispecific antibodies and retargeted cellular cytotoxicity: novel approaches to cancer therapy
Enthalten in International journal of clinical & laboratory research Bd. 22, Nr. 1-4, date:3.1992: 17-20
|
|
|
|
66 |
The potential improvement of thrombolytic therapy by targeting with bispecific monoclonal antibodies: Why they are used and how they are made
Enthalten in Biotherapy Bd. 5, Nr. 3, date:10.1992: 187-199
|
|
|
|
67 |
Retargeting of human lymphocytes against human ovarian carcinoma cells by bispecific antibodies: from laboratory to clinic
Enthalten in International journal of clinical & laboratory research Bd. 21, Nr. 2-4, date:6.1992: 159-164
|
|
|
|
68 |
Bispecific Monoclonal Antibodies Produced by Somatic Cell Fusion Increase the Potency of Tissue Plasminogen Activator
Enthalten in Thrombosis and haemostasis Bd. 64, 1990, Nr. 02: 260-266
|
|
|
|
69 |
A Bispecific Modeling Framework Enables the Prediction of Efficacy, Toxicity, and Optimal Molecular Design of Bispecific Antibodies Targeting MerTK
Enthalten in American Association of Pharmaceutical Scientists: The AAPS journal Bd. 26, 2.1.2024, Nr. 1, date:2.2024: 1-13
|
|
|
|
70 |
AAV-vectored expression of monospecific or bispecific monoclonal antibodies protects mice from lethal Pseudomonas aeruginosa pneumonia
Enthalten in Gene therapy Bd. 31, 27.4.2024, Nr. 7-8, date:7.2024: 400-412
|
|
Administration
